Ligand Pharmaceuticals Inc (LGND)
114.58
+0.64
(+0.56%)
USD |
NASDAQ |
Dec 20, 16:00
115.00
+0.42
(+0.37%)
After-Hours: 20:00
Ligand Pharmaceuticals Price to Book Value: 2.574 for Dec. 20, 2024
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Cellectar Biosciences Inc | 6.260 |
| Revance Therapeutics Inc | -- |
| Pieris Pharmaceuticals Inc | -- |
| Zymeworks Inc | 2.654 |
| CNS Pharmaceuticals Inc | 1.904 |
Price to Book Value Related Metrics
| PE Ratio | 45.65 |
| PS Ratio | 13.58 |
| PEG Ratio | 0.2255 |
| Price to Free Cash Flow | 296.99 |
| Price | 114.58 |
| Earnings Yield | 2.19% |
| Market Cap | 2.165B |
| PEGY Ratio | 0.2255 |
| Operating PE Ratio | 115.12 |